<DOC>
	<DOCNO>NCT00113698</DOCNO>
	<brief_summary>This study evaluate efficacy safety angiotensin convert enzyme inhibition ( ACE-I ) therapy treatment mitral regurgitation ( MR ) .</brief_summary>
	<brief_title>Angiotensin Converting Enzyme Inhibition Children With Mitral Regurgitation</brief_title>
	<detailed_description>BACKGROUND : MR cause volume overload hemodynamic burden leave ventricle . Initial compensatory mechanism may fail , lead increase severity . Patients repair atrioventricular septal defect ( AVSD ) select study relatively high incidence moderate MR regurgitant orifice mobile dynamic , contribute likelihood might respond medical therapy . DESIGN NARRATIVE : This randomize , double-blind , placebo-controlled trial ACE-I therapy child less 18 year age least moderate MR least 6 month postoperative repair AVSD . A non-randomized Observational Phase enrol 181 child less 6 month postoperative repair AVSD , evaluate 6 month trial eligibility .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Mitral Valve Insufficiency</mesh_term>
	<mesh_term>Heart Septal Defects</mesh_term>
	<mesh_term>Congenital Abnormalities</mesh_term>
	<mesh_term>Heart Defects , Congenital</mesh_term>
	<mesh_term>Heart Septal Defects , Ventricular</mesh_term>
	<mesh_term>Enalapril</mesh_term>
	<mesh_term>Enalaprilat</mesh_term>
	<criteria>Children le 18 year age least 6 month post AVSD repair reoperation At least moderate MR Asymptomatic minimally symptomatic , define Ross Heart Failure Class I II Atrioventricular synchrony ( paced intrinsic ) Tetrology Fallot , total partial anomalous venous connection More trivial MS outflow obstruction Other source LV volume overload Hypertrophic obstructive cardiomyopathy Significant residual coarctation</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>March 2014</verification_date>
</DOC>